Table 1 Laboratory results and clinical data of HCC, HCV and MC patients (*p-values were calculated using one-way ANOVA), nd: not detected, N/A: not applicable
Patient characteristics | HCC (n = 69) | HCV (n = 23) | MC (n = 10) | p-value* |
|---|---|---|---|---|
Age (years), n (%) | ||||
≤ 65 | 17 (25%) | 20 (87%) | 4 (40%) | < 0.0001 |
> 65 | 52 (75%) | 3 (13%) | 6 (60%) | |
Gender, n (%) | ||||
Male | 49 (71%) | 14 (61%) | 5 (50%) | 0.3354 |
Female | 20 (29%) | 9 (39%) | 5 (50%) | |
AFP (ng/mL), n (%) | ||||
≤ 20 | 34 (49%) | 22 (95%) | 10 (100%) | 0.4973 |
> 20 | 35 (51%) | 1 (5%) | 0 | |
CA19-9 (U/mL), n (%) | ||||
≤ 37 | 41 (59%) | nd | nd | |
> 37 | 28 (41%) | nd | nd | |
CEA (ng/mL), n (%) | ||||
≤ 3 | 24 (35%) | nd | nd | |
> 3 | 45 (65%) | nd | nd | |
ALT (U/L), n (%) | ||||
≤ 33 | 6 (9%) | nd | 4 (40%) | 0.0196 |
> 33 | 63 (91%) | nd | 6 (60%) | |
AST (U/L), n (%) | ||||
≤ 32 | 6 (9%) | nd | 2 (20%) | 0.266 |
> 32 | 63 (91%) | nd | 8 (80%) | |
GGT (U/L), n (%) | ||||
≤ 40 | 17 (25%) | nd | 7 (70%) | 0.0071 |
> 40 | 52 (75%) | nd | 3 (30%) | |
Tumor size (cm), n (%) | ||||
≤ 4 | 46 (67%) | N/A | N/A | |
> 4 | 23 (33%) | N/A | N/A | |
Tumor nodules, n (%) | ||||
Single | 48 (69.6%) | N/A | N/A | |
Multiple | 21 (30.4%) | N/A | N/A | |
Tumor differentiation, n (%) | ||||
G2 | 69 (100%) | N/A | N/A | |
G3 | 0 | N/A | N/A | |
Child Pugh, n (%) | ||||
A | 60 (87%) | N/A | N/A | |
B | 9 (13%) | N/A | N/A | |